ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

ClinicalTrials.gov ID: NCT05911321

Public ClinicalTrials.gov record NCT05911321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma

Study identification

NCT ID
NCT05911321
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Enrollment
6 participants

Conditions and interventions

Interventions

  • Dexamethasone Drug
  • Isatuximab Drug
  • Pomalidomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 4, 2023
Primary completion
Jun 17, 2025
Completion
Mar 25, 2028
Last update posted
Oct 19, 2025

2023 – 2028

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
2
Facility City State ZIP Site status
Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27514
Atrium Health Wake Forest Baptist Medical Center Winston-Salem North Carolina 27157

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05911321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05911321 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →